Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors

Hawkey, C.J.; Langman, M.J.S.
April 2003
Gut;Apr2003, Vol. 52 Issue 4, p600
Academic Journal
Non-steroidal anti-inflammatory drugs (NSAIDs) are well recognised as causing peptic ulceration and ulcer complications. However, several critical issues, including the amount of both gastrointestinal and non-gastrointestinal disease affected by NSAIDs, their interaction with ancillary risk factors, and how to optimise management in subgroups, remain poorly understood. In this article, strategies for subgroups that take account of non-specific gastrointestinal risks, minimisation of residual risk, and the importance of non-gastrointestinal toxicity are suggested, and areas for research identified.


Related Articles

  • Risk-Management for Persons at High Risk of GI Bleeding.  // Travel Medicine Advisor;Aug2007, Vol. 17 Issue 8, p16 

    The article discusses a study on the appropriate steps for risk reduction in patients taking NSAIDs. There is a risk of rebleeding in persons with a history of ulcer bleeding if traditional NSAID only is administered. The study revealed that COX-2 inhibitors should always be taken together with...

  • Celecoxib Is as Effective as Diclofenac plus Omeprazole at Reducing Ulcer Bleeding. Chan, F. K;; Hung, L. C.; Suen, B. Y. // Annals of Internal Medicine;9/7/2004, Vol. 141 Issue 5, p375 

    This article presents information on effectiveness of various drugs used to treat ulcer bleeding. Current guidelines recommend that patients who are at risk for ulcer disease and require treatment for arthritis should receive either a cyclooxygenase-2 (COX-2) drug or a nonselective nonsteroidal...

  • Reducing the risk of NSAID treatment.  // Australian Journal of Pharmacy;Dec2010, Vol. 91 Issue 1087, p70 

    The article presents research examining the risk of clinical outcomes throughout the gastrointestinal tract in patients treated with cyclo-oxygenase (COX)-2-selective non-steroidal anti-inflammatory drugs (NSAIDs) and non-selective NSAID plus a proton-pump inhibitor, which shows that the risk...

  • Prevention of Ulcers by Esomeprazole in At-Risk Patients Using Non-Selective NSAIDs and COX-2 Inhibitors. Scheiman, James M.; Yeomans, Neville D.; Talley, Nicholas J.; Vakil, Nimish; Chan, Francis K. L.; Tulassay, Zsolt; Rainoldi, Jorge L.; Szczepanski, Leszek; Ung, Kjell-Arne; Kleczkowski, Dariusz; Ahlbom, Henrik; Næsdal, Jørgen; Hawkey, Christopher // American Journal of Gastroenterology;Apr2006, Vol. 101 Issue 4, p701 

    OBJECTIVES: Proton pump inhibitors reduce ulcer recurrence in non-steroidal anti-inflammatory drug (NSAID) users, but their impact in at-risk ulcer-free patients using the current spectrum of prescribed agents has not been clearly defined. We assessed esomeprazole for ulcer prevention in at-risk...

  • NSAID + PPI easier on the stomach than COX-2 inhibitors.  // Reactions Weekly;7/22/2006, Issue 1111, p4 

    The article presents a study by BMR Spiegel and colleagues which states that the use of the non-steroidal anti-inflammatory drugs (NSAID) and proton pump inhibitor (PPI) combination reduces the risk of dyspeptic symptoms than selective COX-2 inhibitor.

  • A hard look at preventing GI bleeds caused by NSAIDs. Paist, Scott S.; Russell, John J. // Patient Care;Jan2005, Vol. 39 Issue 1, p63 

    Discusses research being done on the effectiveness of several strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs. Reference to a study by L. Hooper et al published in a 2004 issue of "British Medical Journal"; Relative risk of symptomatic...

  • Potential alternatives to COX 2 inhibitors. Skelly, M M; Hawkey, C J // BMJ: British Medical Journal (International Edition);6/1/2002, Vol. 324 Issue 7349, p1289 

    Editorial. Discusses the idea that the failure of the celecoxib long term arthritis safety study, the CLASS trial, might be due to the design of the trial rather than the inadequacies of cyclo-oxygenase-2 (COX 2) inhibitors. Topics of non-steroidal anti-inflammatory drugs, gastroduodenal...

  • A COX-2-Specific Inhibitor Plus a Proton-Pump Inhibitor: Is This a Reasonable Approach to Reduction in NSAIDs' GI Toxicity? Cryer, Byron // American Journal of Gastroenterology;Apr2006, Vol. 101 Issue 4, p711 

    The two prevailing approaches to decrease risks of nonsteroidal anti-inflammatory drug (NSAID)-associated gastrointestinal (GI) events are the use of a COX-2 inhibitor or co-therapy with a proton-pump inhibitor (PPI). A major limitation of each approach is that, in patients at the highest risk...

  • COX-2 selective treatment reduces gastrointestinal side effects. Siddall, Rhonda // British Journal of Hospital Medicine (17508460);Aug2010, Vol. 71 Issue 8, p431 

    The article offers information on a study related to the therapeutic effects of cyclo-oxygenase-2 (COX-2) in gastrointestinal side effects.


Read the Article


Sign out of this library

Other Topics